Posted on

Novamind Closes Arizona Acquisition

Novamind Closes Arizona Acquisition

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

TORONTO, ON / January 18, 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, announces that, further to its press release dated December 23, 2021, it has closed its acquisition (the “Acquisition”) of Arizona-based Foundations for Change, Inc. (“Foundations”), a mental health practice specialized in ketamine-assisted psychotherapy.

“We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”

With the closing of the Acquisition, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, assumes the role of Medical Director at the Peoria and Phoenix clinic locations.

Mr. Edelman commented: “Joining Novamind is the right fit for our team and aligns with our mission to provide innovative and compassionate mental healthcare. I would like to thank our patients, partners and community for their ongoing support over the years. We look forward to integrating our team and operations with Novamind and benefiting from its deep expertise and infrastructure as we continue to serve a growing patient population.”

In connection with the Acquisition, the Company issued 441,261 common shares in the capital of the Company (the “Shares”) pursuant to the terms of debt settlement agreements entered into with certain holders of debt of Foundations (the “Debtholders”), at a deemed price per share equal to CAN$0.468 per Share. The Shares are subject to a statutory hold period expiring on May 18, 2022 in accordance with applicable Canadian securities laws and the policies of the Canadian Securities Exchange. The Company also paid to the Debtholders an aggregate of US$336,955 cash. The Company’s news release dated December 23, 2021 provides additional details for the consideration payable by the Company pursuant to the Acquisition.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Investor Relations
Email: IR@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Cautionary Statement
The securities of the Company referred to in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this news release.

Posted on

Docs on Mushrooms: issue 32

Hello and welcome back.

We’re excited to announce that we’ll be bringing you a FREE virtual event on February 3rd to discuss all things psychedelic and mental health. If your New Year’s resolution is to work on your mental health, you won’t want to miss it! Keep reading for details 😊

Here’s what’s in store for you in today’s issue:

🍄 The most intense psychedelic?

🍄 Impressive findings from a ketamine study on addiction

🍄 A promising treatment for ALS

🍄 Rescheduling psilocybin GLOBALLY

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

What physicians really think about psilocybin

On this episode of the Daily Mushroom Podcast, we have Dr. Lyle Oberg, co-founder, and CEO of MYND life sciences. Dr. Oberg has been had an extensive career across many sectors, including working as a family physician and a Chief Policy and Medical Officer at a cannabis company. He was also part of the Alberta government for 15 years as Minister of Finance, Social Services, Learning, and more. Stick around to hear what Dr. Oberg has to say, we are sure it will give a new insight into the world of psychedelics!

Therapeutic banner

86% abstinent after ketamine therapy

Six months after receiving three ketamine infusions and Awakn Life Sciences’ proprietary therapy, 86% of patients with severe alcohol use disorder remained abstinent from alcohol. 

Awakn’s study also showed that:

  • The treatment was 2.7x more effective than placebo infusions and alcohol education
  • Risk of mortality within one year dropped from 1 in 8 patients to 1 in 80
  • Liver function improved (shocker)
  • Depression scores were significantly reduced
  • Ability to experience pleasure increased

The downside? There isn’t one. There were no serious adverse reactions either 👏

Slowing the progression of ALS

When diagnosed with ALS, patients are typically given 2 to 6 years to live and experience rapid decline in muscle function. Even after the ice bucket challenge took the internet by storm, a cure has yet to be found. 

Luckily, ketamine is showing potential to slow the progression of the disease to improve both the quality and length of patients’ lives.

In a mouse model of ALS, PharmaTher (PHRM) found that ketamine preserved muscle function and increased life expectancy if administered in the early stages of the disease. 

The company received FDA approval for a Phase II trial that will assess a biomarker of neurodegeneration, functional abilities, muscle strength, and depression scores among ALS patients undergoing ketamine treatments.

Psilocybin + CBD 🧠

The majority of patients with traumatic brain injury (TBI) also experience depression, and patients with severe TBI-related depression are 5x more likely to attempt suicide.

Wesana Health (WESA) is planning a study to see if the condition can be treated with one large dose of psilocybin in a clinic, followed by “self-administered maintenance doses” of psilocybin and CBD to sustain the benefits.

Researchers believe the treatment will promote neuroplasticity and neurogenesis while reducing neuroinflammation.

Can ketamine enhance addiction medication?

Novamind (NM) is hosting a first-of-its-kind study to find out.

The trial will see if ketamine-assisted therapy can enhance the effectiveness of buprenorphine, a first-line addiction medication, in treating opioid use disorder. 

Will the two drugs finally be able to conquer this treatment-resistant condition?

inspirational banner

Join our virtual Mental Health Town Hall

We’re collaborating with experts at Entheon Biomedical (ENBI) to bring you a special virtual event on February 3rd. 

Here’s what you can expect to learn:

  • The latest psychedelic research on mental health and addiction
  • How psychedelics can be used for personal development
  • All things microdosing
  • Where the industry is headed
  • Answers to all your burning questions

You’ll hear insights and stories from:

  • Timothy Ko, CEO and Founder of Entheon
  • Dr. Andrew Greenshaw, Scientific Advisor to Entheon and Professor of Psychiatry and Neuroscience at the University of Alberta
  • David Mayoh, Communications Manager at Entheon
  • Thomas Hartle, the first Canadian to receive psilocybin therapy
  • And more

Now is your chance to get your questions answered by industry experts and connect with fellow members of the Daily Mushroom Community. We can’t wait to see you there. Register now 👇

The most intense psychedelic?

“​​I truly doubt that there is another psychedelic drug, anywhere, that can match [4-HO-DiPT] for speed, intensity, brevity, and sensitive to dose, at least one that is active orally.”

Field Trip Health’s (FTRP) first novel compound could produce the most intense experience of any oral psychedelic. 

It’s a more stable and soluble version of 4-HO-DiPT — a drug that induces an extremely powerful experience lasting 2-3 hours, according to Alexander Shulgin, the chemist who created it.

Considering he’s experimented with 55 different psychedelics, which he reviewed in “Tryptamines I Have Known and Loved,” we’ll take his word for it. 

Field Trip expects to receive a patent for the formulation next month. 

business banner

Mydecine (MYCO) is launching a program to sell MDMA and psilocybin, as well as training and support services, to healthcare practitioners through Health Canada’s amended Special Access Program. The company also completed a model that can rapidly screen billions of compounds using AI to find novel psychedelics that bind to serotonin receptors. 

Delic Holdings Corp. (DELC) announced that it plans to more than double its footprint in the next 18 months by opening 15 new ketamine clinics, which will be strategically located in secondary cities to improve patient accessibility.

Ketamine One (MEDI) began trading on the OTCQB marketplace under the symbol ‘KONEF’.

atai Life Sciences (ATAI) received FDA approval for a study to investigate how its R-ketamine compound interacts with other drugs.

legal banner

Rescheduling psilocybin GLOBALLY 🌍

“Given today’s scientific understanding of psilocybin’s high potential therapeutic value and low risk of dependence, a change of its status as a Schedule I drug is long overdue,” according to Christopher Koddermann.

That’s why he co-founded The International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) – an initiative that’s pushing for psilocybin to be rescheduled on a global scale.

ITPRI aims to reschedule psilocybin through the United Nations’ Convention on Psychotropic Substances, which was enacted over 50 years ago 😮 This would significantly reduce the regulatory barriers that impede psilocybin research and access to treatment.

So yes, rescheduling is long overdue, but better late than never!

Plus, progress in the US & Italy:

  • A Missouri Rep. filed a bill to expand the state’s right-to-try law to include psilocybin, MDMA, DMT, ibogaine, LSD, mescaline, and peyote. This would grant patients with serious illnesses legal access to the substances. Read more…

  • Senator Scott Wiener announced that he is once again pushing for a psychedelic decriminalization bill in California after halting it last year, and believes it has a 50/50 chance of being passed. To generate support, veterans are meeting with Assembly members and changes may be made to possession limits and types of psychedelics included. Read more…

  • Virginia lawmakers introduced a bill to reduce the penalty for possessing peyote, ibogaine, psilocybin, or psilocin from a Class 5 felony to a $100 fine. A separate bill focused on just psilocybin and psilocin was also filed. Read more…

  • Italian officials verified 630,000 signatures collected in support of a measure to decriminalize cultivation of marijuana and psilocybin mushrooms. If the measure is approved by the Constitutional Court, which will be announced on February 15, it will appear on a ballot this spring. Read more…

Turning mushrooms into mush houses

Architect David Benjamin wants to make the construction industry more sustainable using (you guessed it) mushrooms!

He constructed a 40-foot-tall structure using bricks grown from mushroom mycelium. 

The bricks are lightweight yet durable and can be grown in five days without emitting carbon or producing waste.

Video of the Week

The Battle Over Psychedelic Therapy’s Future

Playlist of the Week

Trippy Songs 🍄🍃👽🚀
Posted on

Novamind Unveils New Design Concept for Clinics

Novamind Unveils New Design Concept for Clinics

TORONTO, ON / January 5, 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, today unveiled its clinic design concept (the “Design Concept”) to accommodate the unique requirements of psychedelic-assisted psychotherapy. The Design Concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.

Inclusive and welcoming, the Design Concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:

  • Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
  • Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
  • Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
  • Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA

To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.

“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”

Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”

To see renderings of the Design Concept, click here.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About DesignAgency
DesignAgency is an award-winning international design studio that draws on over two decades of expertise in interior design, architectural and landscape concepting, strategic branding, and visual communications. With studios in Toronto, Washington, D.C., Los Angeles and Barcelona, DesignAgency has developed a global reputation for creating exceptional environments that people experience fully and deeply. Key to our success is the strength of collaboration. Our talented design teams are informed by curiosity, international perspectives, and a drive for innovation. Working across hospitality, residential, commercial, and retail sectors, we work with our clients and with local and international artists, craftspeople, and suppliers to realize extraordinary experiences and lasting value.

Contact Information
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Investor Relations
Email: ir@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

🎄 Family Christmas dinner discussion ideas 🍄: issue 29

Merry Christmas Eve everyone!

Did you know that many popular Christmas traditions likely originated from psychedelic mushroom rituals? Be sure to check out the Video of the Week to learn more!  

If you need something to discuss over Christmas dinner, keep reading to learn how psychedelics allegedly ended the Cold War 😮 

Here’s what’s in store for you in today’s issue:

🍄 Why psychedelics could be the key to world peace 🔑

🍄 The common flower that can make you trip?!

🍄 Fixing brain damage at home

🍄 Another city decriminalizes psychedelics 🎉

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

A special episode : Our host Brett recounts a recent psilocybin therapy session with his guide Adrian as the guest.

 
This episode has been published and can be heard everywhere your podcast is available.
In this very special episode, our host Brett, recounts his first hand experience of a recent psilocybin assisted psychotherapy session. His guest Adrian ,was his guide through the whole process !

Adrian Oberg started the organization VAPS ( Victoria Association of Psychedelic Study ) He has a background working in harm reduction and has been guiding people through psychedelic therapy sessions for the last 5 years.

Therapeutic banner

Fixing brain damage at home

Evidence suggests that microdosing improves cognitive function and memory. This kit could take the benefits up a notch.👇🏽

Ixtlan Bioscience, a private Israeli company, filed a US patent for a microdosing kit that can be used at home to treat Alzheimer’s, brain damage, and neuronal disorders.

The kit includes:

  • Psilocybin capsules
  • Games and exercises to enhance the benefits of microdosing
  • A web application that patients can use to track their progress.

Who knows, maybe this time next year, it’ll be the trending gift to put under the tree. 🎄

Take this test before your first ayahuasca retreat

HaluGen Life Sciences expanded its psychedelic DNA test – it can now assess how your body metabolizes LSD, MDMA and ayahuasca. 

The kit tests for a CYP2D6 gene mutation, which can cause metabolism of the drugs to take up to twice as long. This could lead to longer, more intense trips and adverse reactions. 

Thankfully, the mutation is only present in 5-10% of people!

The findings from COMPASS’s depression study keep coming!

COMPASS Pathways’ (CMPS) announced that patients taking SSRI antidepressants in conjunction with psilocybin therapy had similar outcomes and fewer side effects compared to those who withdrew from SSRIs before the study.

Five patients who withdrew from SSRIs had serious adverse effects, such as suicidal ideation, when given the largest dose. None of the patients on SSRIs had this experience. 

inspirational banner

Why psychedelics could be the key to world peace

This scientist claims she helped end the Cold War with MDMA.

Carol Rosin—a space and missile defense consultant for the US—said she gave MDMA to Soviet scientists and military personnel prior to nuclear negotiations in 1985 (before the drug was illegal).

The plan was created with help from Rick Doblin, the founder of MAPS. 

“The thought was that if they can work through their fears and traumas and feel their connection to humanity, then that might be helpful,” Doblin explains.

While some are skeptical if this actually happened, MDMA releases oxytocin (aka the hormone of love and empathy), which could certainly help the opposing sides see eye to eye!  

Most addiction specialists see promise in psychedelic treatments!

A recent survey revealed how psychedelic therapy is viewed by medical professionals in the American Academy of Addiction Psychiatry.

Of the 145 respondents:

  • 64% believe that psychedelics show promise in treating substance use disorders
  • 82% agree that the drugs show promise in treating psychiatric disorders like depression
  • 75% were in favour of legalizing psychedelics for therapeutic uses

Interest is growing among patients too – the vast majority of specialist said they had discussed psychedelic experiences with at least one patient.

Fill out our quick survey so we can deliver more of what you want!

Nature’s acid ✿

This common flower can make you trip?! 

The seeds of Morning Glory flowers contain a hallucinogenic compound that’s similar to LSD. It’s said to induce a dreamlike state and was even used in Mayan rituals to communicate with spirits.

(However, it can also cause nausea, vomiting, and cramping, so do with that information what you will 😉)

Research on the plant is gaining traction, so we may see it in clinical trials in the near future.

business banner

Pasithea Therapeutics (KTTA) opened its second ketamine clinic in London to treat PTSD and treatment-resistant depression.

Maya Health raised $4.3M to decentralize psychedelic research. The company is developing a blockchain-based platform that allows the psychedelic community to collaborate, share best practices, and gather real-world data to accelerate pre-clinical research.

HAVN Life (HAVN) entered into an agreement to acquire Spore Life Sciences, a subscription-based functional mushroom company with current sales exceeding $1M per month.

Novamind (NM) is planning to acquire two Arizona-based ketamine clinics from Foundations for Change. The founder of Foundations for Change, who specializes in treating veterans and first responders, will be the Medical Director of both clinics. 

Cybin (CYBN) and Tryp Therapeutics (TRYP) announced end-of-year business highlights.

legal banner

Here’s what you missed in the legal world:

  • Port Townsend became the second city in Washington to decriminalize psychedelics after a unanimous council vote! Read more…
  • Activists in Colorado submitted an initiative for statewide decriminalization of psychedelics, which will likely appear on the 2022 ballot. Read more…
  • The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) changed its guidelines to allow the use of “real-world data” collected from the healthcare system to aid in regulatory approval of new medicines. This will expedite clinical trials and get treatments to patients sooner! Read more…
  • The FDA put a clinical hold on MindMed’s study on LSD for anxiety. The reason for doing so is unclear, but more details are expected within 30 days. Read more…

Turning oil into soil

Millions of liters of oil are spilled into the ocean every year. Mushrooms (once again) come to the rescue!

Mats made of human hair have been used to effectively clean up oil spills – they soak up over 15 times their weight in oil.

Oyster mushrooms thrive in oily environments and can easily be grown on the mats. In just 12 weeks, they can transform the black gunk into nontoxic soil!

Video of the Week

The Magic Mushroom Christmas Theory

Playlist of the Week

Psychedelic Chill
Posted on

Your relatives 🤬 Christmas 🎄 and Psychedelics 🍄: issue 27

Here’s what’s in store for you in today’s issue:

🍄 First psychedelic studies program in Canada

🍄 How to cure depression in two hours 🤯

🍄 Psilocybin works twice as well as nicotine patches!

🍄 Two stock that could quadruple in price 📈

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Can DMT really help cure addiction?

In this episode of the Daily Mushroom Podcast, we have David Mayoh, communication manager for Entheon Biomedical. David talks about how psychedelic therapy changed his life and how DMT can help those who are suffering from addiction.

How to cure depression in two hours

GH Research (GHRS) discovered that the most powerful psychedelic, 5-MeO-DMT (aka toad venom), is highly effective at curing treatment-resistant depression.

Out of eight patients, seven were in remission from depression just one day after receiving the company’s proprietary formulation, and five of those were in remission in as little as two hours. 

All eight patients showed improved depression scores, with an average reduction of 76%. 

Psilocybin works twice as well as nicotine patches!

Dr. Matthew Johnson’s research found that 59% of nicotine-addicted patients remained abstinent from smoking for 12 months after receiving a single macrodose of psilocybin. Only 28% of patients on a nicotine patch remained abstinent for the same time period.

His other research shows that multiple psilocybin doses can have an 80% success rate!

Psychedelics → spirituality → emotional regulation → happiness

A recent survey shows that spirituality increases with psychedelic use, and that increased spirituality is linked to improved emotional regulation. The findings suggest that better emotional regulation is associated with decreased scores for depression, anxiety, and disordered eating.

Reboot your brain 

Marcus Capone, a former Navy SEAL who was battling PTSD, finally got his life back after travelling to Mexico for an ibogaine treatment. 

He instantly felt like a huge weight had been lifted, as if his brain “was rebooted like a new operating system.”

“You can’t hide from the medicine. It’s going to reach down and it’s going to pull out everything that is affecting you,” he explains.

Ibogaine is a psychedelic substance found in the root  bark of the iboga tree! Learn more here.

The first psychedelic studies program in Canada

This semester, the University of Ottawa launched a three-course “microprogram” on Psychedelics and Spirituality. The school will offer a master’s program in psychedelics in the fall of 2022 and aims to develop a Ph.D. program after that!

Why?

“I was getting emails almost on a daily basis from people who wanted to know how they could become psychedelic therapists,” said Dr. Monica Williams, who created the program.

US government studies ibogaine

Delix Therapeutics, a private Boston-based company, is partnering with The National Institute on Drug Abuse (NIDA) to develop a treatment for substance abuse. The partnership will evaluate Delix’s non-hallucinogenic formulation of ibogaine, which has already shown promise of reducing alcohol- and heroin-seeking behavior.

BetterLife Pharma (BETR) found that its LSD formulation successfully increased exploratory and grooming behaviours in rats, two indicators of an antidepressant effect.

atai Life Sciences (ATAI) launched TryptageniX, a majority-owned joint venture with CB Therapeutics that will focus on discovering new compounds, both psychedelic and non-psychedelic.

Mycotopia Therapies (TPIA) is planning a $360M merger with Ei.Ventures to form PSLY.COM and intends to list on the NASDAQ. The new company would focus on Ei.Ventures’ flagship product Psilly, which combines psilocybin with other plant and fungi extracts for a synergistic effect.

Vine Ventures and MAPS formed a $70M special purpose vehicle called the Regenerative Financing Vine to fund MDMA research for PTSD and promote patient access.

An analyst at H.C. Wainwright predicted that Field Trip Health’s (FTRP) and COMPASS Pathways’ (CMPS) stocks could quadruple in value in the next 12 months! 🤑

GH Research (GHRS) and Numinus Wellness (NUMI) announced their financial highlights.

legal banner

Here’s what you missed in the legal world:

The Drug Enforcement Administration (DEA) and National Institute On Drug Abuse (NIDA) showed support for Biden’s plan to accelerate research on cannabis and certain psychedelics. The plan would reduce the requirements to research Schedule I substances, making them more similar to the Schedule II requirements. Read more…

 

4,000% of your daily vitamin D

The majority of people are deficient in vitamin D. Mushrooms could provide a solution!

Wild mushrooms are rich in the vitamin, but commercial production (which is often done in the dark) reduces concentration levels.

Scientists discovered that exposing mushrooms to UV radiation can increase vitamin D levels to over 4,000% of your daily value per serving! The exposure also causes mushrooms to produce more antioxidants and anti-inflammatory molecules.

Industry Quick Hits

Dec 6 – Novamind (NM) Opens New Salt Lake City Clinic with Specialized Focus on Substance Use Disorders Read more…

Dec 6 – Mydecine (MYCO) Files Full Patent Application Covering Multiple Families of Psilocin Analogs Read more…

Dec 8 – Ketamine One (MEDI) Adds Seattle Location To US Clinical Network Read more…

Dec 8 – Silo Wellness (SILO) Announces U.S. DTC Eligibility Read more…

Dec 8 – Nue Life announces donations to MAPS and Ketamine Research Foundation  Read more…

Dec 9 – Cannabis company Nextleaf Solutions (OILFF) Receives a Controlled Substance Dealers License Read more…

Video of the Week

Chinese mushrooms grown in 'smart greenhouses' spur multimillion dollar business

Playlist of the Week

Psychedelic Chill
Posted on

Want a life-changing psychedelic trip but don’t know where to start?: issue 26

Here’s what’s in store for you in today’s issue:

🍄 The cure for the worst pain known to humans

🍄 Combining antidepressants and psilocybin

🍄 More positive findings from biggest psilocybin trial

🍄 Psychedelic cream?

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

Why a psychedelic retreat might be the best vacation you’ve ever been on

In this episode of the Daily Mushroom Podcast, we have the CEO of Silo Wellness, Douglas Gordon. Silo Wellness offers legal, psychedelic retreats in Jamaica and Oregon. Their mission is heavily rooted in the education around the physical and mental benefits of mushrooms. We hope you enjoy this one!

Antidepressants + psilocybin

Do patients need to come off of antidepressants before trying psilocybin therapy?

New research from MindMed (MNMD) and Liechti Labs suggests that it’s not necessary – and there are actually benefits of combining the two.

Escitalopram (aka Lexapro) did not affect the way psilocybin was processed and helped reduce negative side effects like anxiety and high blood pressure.

More positive findings from biggest psilocybin trial

COMPASS Pathways (CMPS) announced additional findings from the world’s largest psilocybin trial for depression. 

In addition to reduced depression scores, patients showed improvements in anxiety, daily functioning, cognition, and quality of life. Just one day after the treatment, patients had increased positive feelings such as “interested, excited, strong” and decreased negative feelings like “distressed, upset, afraid.” 

Psychedelic cream

Psycheceutical Inc., a private Florida company, is developing a unique way to deliver psychedelics – through a cream or patch applied to the back of the neck. This method allows psychedelics to enter the brain in just 5-10 minutes without entering the bloodstream, which reduces negative side effects.

Participate in psychedelic research from your phone!

Quantified Citizen is a platform made in collaboration with Paul Stamets to accelerate health research. It allows anyone to participate in studies anonymously from their phone.

The platform was used to conduct the world’s largest mobile microdosing study, which revealed that microdosers exhibit lower levels of depression, anxiety, and stress.

It’s not too late to participate – download the app here to join the study!

Curing the worst pain known to humans

For years, Brad Badelt suffered from debilitating cluster headaches (which are often called “suicide headaches” and described as the worst pain known to humans.

After seeing countless neurologists, chiropractors, acupuncturists, and naturopaths, he would still experience the horrible headaches several times a day for weeks on end.

After taking one dose of shrooms, things finally changed. 

“When I woke the next morning, I felt different: the mental fog brought on by my cluster headaches was gone. For the next twelve months, I remained headache free. Every year since, I’ve downed a dose of shrooms, and every year my cluster headaches have remained in remission.”

Want a life-changing psychedelic trip but don’t know where to start?

The Wakeful Integration Journal is your guide to transformation. 

It’s the ultimate tool to help you prepare for, navigate, and deeply integrate your psychedelic experiences. The journal features:

  • Prompts to discover your intentions and reflect on your trip
  • Dose tracking
  • Tips to support you along the journey
  • Colouring pages to unlock your creativity

If you want to start with microdosing rather than a full-on trip, the Wakeful Intention Journal is for you! It guides you through a 6-week microdosing protocol and helps you set intentions, notice patterns, and integrate your insights.

Support the Kickstarter here to receive a journal and begin your transformation journey!

The Canadian government is funding psychedelic research!

MYND Life Sciences (MYND) received $45,600 in government funding to support a psilocybin research project on treatment resistant depression and neuroinflammation. The project will run now until March 2022.

Novamind (NM) partnered with Bienstar Wellness to develop the first network of integrative mental health clinics in Latin America. The companies plan to bring psychedelic medicine to Uruguay, Brazil, Mexico, Peru, and Panama.

PharmaTher (PHRM) was granted a Japanese patent for KETBET, a combination of ketamine and betaine anhydrous that can be used for various mental health and pain disorders. Betaine anhydrous enhances the antidepressant effect of ketamine while reducing the side effects.

Telescope Innovations (TELI) acquired the rights to the University of British Columbia’s research on synthetic psilocybin in exchange for 1M common shares at $0.99 each.

Bright Minds Biosciences (DRUG) announced that its drug discovery program has synthesized hundreds of patentable psychedelic compounds. Researchers are optimizing the most encouraging molecules and aim to announce the lead molecule early next year.

Shanti Therapeutics, a subsidiary of Global Wellness (GWS), is awaiting ethics committee approval to conduct one of the first studies on MDMA for pain management. 

These companies announced their financial highlights:

legal banner

Here’s what you missed in the legal world:

  • New Zealand is legalizing drug testing so users can check the purity of illegal substances. The services will be available at events like concerts and festivals. Read more…
  • The DEA is once again increasing the production quotas of these psychedelic drugs for 2022: 
    • Psilocybin increased from 3,000 to 8,000 grams
    • Psilocin increased from 2,000 to 3,000 grams
    • MDMA increased from 3,200 to 8,200 grams
    • DMT increased from just 250 to 3,000 grams

          The new limits will allow more researchers to study the drugs! Read more…

  • A Florida Rep. filed a bill to decriminalize all illegal substances and implement rehabilitative health intervention or civil fines instead. Read more…

Eco-friendly funerals

A startup in the Netherlands is making biodegradable “living coffins” out of mushroom mycelium!

Not only do the coffins enrich the soil, but they allow “people to become one with nature again.” 

After months of testing, the first funeral using a mushroom coffin was a success.

Bob Marley mushrooms 🇯🇲

Silo Wellness (SILO) launched a line of functional mushroom products in collaboration with Bob Marley’s family!

The Marley One line features:

  • One Mind: A coffee-flavored blend of lion’s mane and gingko biloba designed to improve focus and cognitive function.
  • One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function.
  • One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion.
  • One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health.
  • One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep. 

Use promo code DAILYMUSHROOM20 to get 20% off! 

Shop Marley One

Industry Quick Hits

Nov 29 – Numinus (NUMI) Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans Read more…

Nov 29 – atai Life Sciences (ATAI) Increases its Ownership Position in COMPASS Pathways (CMPS) Read more…

Nov 30 – Cybin (CYBN) Announces FDA IND and IRB Approvals for Clinical Trial to Treat Frontline Clinicians with COVID-Related Distress Read more…

Dec 2 – Ketamine One (MEDI) Partners with Cognetivity Neurosciences in Collaborative Clinical Study on Depression and PTSD Read more…

Dec 2 – Tryp Therapeutics (TRYP) Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia  Read more…

Nov 26 – Delic Corp’s (DELC) Ketamine Wellness Centers Opening Salt Lake City & Reno Locations Read more…

Video of the Week

How LSD Triggered a Psychedelic Revolution

Playlist of the Week

Psychedelic Chill
Posted on

Novamind to Present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6

Novamind to Present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6

TORONTO, ON / December 2, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will present at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021.

Novamind’s CEO and Director, Yaron Conforti, will join the Psychedelics Assisted Psychotherapy panel discussion from 1:30 PM to 2:15 PM EST. Mr. Conforti will also deliver a corporate presentation to update investors on recent milestones and progress towards the global expansion of Novamind’s psychedelic clinics and research sites.

For more information about the event and to register, visit https://hcwevents.com/psychedelics.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Investor Relations
Email: IR@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America’s First Integrative Mental Health Clinic Network

Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America’s First Integrative Mental Health Clinic Network

Novamind (NM) partnered with Bienstar Wellness to develop the first network of integrative mental health clinics in Latin America. The companies plan to bring psychedelic medicine to Uruguay, Brazil, Mexico, Peru, and Panama.

PDF of Article